JJP Biologics
  • Home
  • About Us
    • Procurement
    • ABM Projects
  • Pipeline
  • Careers
  • Newsroom
  • Contact
  • Privacy Policy
  • Terms and conditions
  • Cookie policy
  • pl_PL
  • en_GB
JJP Biologics
JJP Biologics
  • Home
  • About Us
    • Procurement
    • ABM Projects
  • Pipeline
  • Careers
  • Newsroom
  • Contact
  • Privacy Policy
  • Terms and conditions
  • Cookie policy
  • pl_PL
  • en_GB
21/12/2022

Zapytanie z dnia 21/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

20/12/2022

Zapytanie z dnia 20/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

14/12/2022

Medical Research Agency

Project “Development of first-in-class antibody therapy for treatment of the ultra-rare LABD indication as well as for pulmonary and autoimmune diseases…

Read more

06/12/2022

Zapytanie z dnia 06/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

06/12/2022

Zapytanie z dnia 06/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

06/12/2022

Zapytanie z dnia 06/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

06/12/2022

Zapytanie z dnia 06/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

05/12/2022

Zapytanie z dnia 05/12/2022

W zwiÄ…zku z realizacjÄ… projektu rozwoju kandydata na lek o tytule „Development of first-in-class antibody therapy for treatment of the…

Read more

News
18/03/2021

High S1-specific IgA antibody levels discriminate severely ill SARS-CoV-2 patients

High S1-specific IgA antibody levels discriminate severely ill SARS-CoV-2 patients. The virus acts as high avidity matrix for neutrophils to…

Read more

Posts pagination

< Page 1 Page 2 Page 3 Page 4
JJP Biologics
Main Office
Bobrowiecka 6, 00-728
Warsaw, Poland
+48 887 860 023
Useful Links
  • Home
  • About Us
    • Procurement
    • ABM Projects
  • Pipeline
  • Careers
  • Newsroom
  • Contact
  • Privacy Policy
  • Terms and conditions
  • Cookie policy
  • pl_PL
  • en_GB

JJP Biologics 2025. All Rights Reserved.